Table 2.
Univariate analyses for progression-free survival and overall survival.
| PFS | OS | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| RDW (%) | 1.69 | 1.05–2.75 | 0.031 | — | — | 0.238 |
| Age (year) | — | — | 0.173 | 1.04 | 1.02–1.07 | 0.001 |
| Sex (male) | — | — | 0.591 | — | — | 0.835 |
| ECOG (≥2) | 1.89 | 1.05–3.41 | 0.034 | 1.82 | 1.01–3.28 | 0.048 |
| Hemoglobin (g/dL) | 0.88 | 0.79–0.99 | 0.028 | 0.86 | 0.76–0.99 | 0.029 |
| Platelet (×109/L) | — | — | 0.633 | 0.99 | 0.99-1.00 | 0.001 |
| Creatinine (mg/dL) | — | — | 0.539 | — | — | 0.127 |
| Calcium (mg/dL) | — | — | 0.435 | — | — | 0.443 |
| Albumin (g/dL) | 0.56 | 0.36–0.86 | 0.008 | 0.48 | 0.31–0.74 | 0.001 |
| LDH (IU/L) | 1.84 | 1.00–3.38 | 0.050 | — | — | 0.195 |
| B2MG (mg/dL) | 1.08 | 1.03–1.14 | 0.002 | 1.07 | 1.03–1.10 | <0.001 |
| M-protein (g/dL) | — | — | 0.475 | — | — | 0.802 |
| Light chain disease | — | — | 0.722 | — | — | 0.282 |
| Nonsecretory type | — | — | 0.504 | — | — | 0.247 |
| Plasmacytoma | — | — | 0.163 | — | — | 0.410 |
| Cytogenetic risk (high) | — | — | 0.134 | — | — | 0.083 |
| Induction with novel agents* | — | — | 0.542 | — | — | 0.711 |
| ASCT | — | — | 0.143 | 0.2 | 0.09–0.47 | <0.001 |
*Induction with bortezomib, thalidomide, or renalidomide.
HR: hazard ratio; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; B2MG: β2-microglobulin; LDH: lactate dehydrogenase; ASCT: autologous stem cell transplantation; RDW: red blood cell distribution width.